Literature DB >> 22771885

Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.

Hye Jin Baek1, Ho Sung Kim, Namkug Kim, Young Jun Choi, Young Joong Kim.   

Abstract

PURPOSE: To test the predictive value of skewness and kurtosis changes of normalized cerebral blood volume (nCBV) during the early treatment period for differentiating early tumor progression from pseudoprogression in patients with newly diagnosed glioblastomas.
MATERIALS AND METHODS: The institutional review board approved this retrospective study. The authors assessed 135 patients with newly diagnosed glioblastomas who underwent concurrent chemotherapy and radiation therapy (CCRT) after surgical resection. Patients who developed new or enlarged contrast material-enhanced lesions after CCRT were assessed by means of conventional and perfusion magnetic resonance (MR) imaging. The percent change of skewness and kurtosis on nCBV histograms between the first and second post-CCRT follow-up were classified into four categories. Independent predictors of early tumor progression were determined by means of logistic regression analysis.
RESULTS: Of 135 patients, 79 had new or enlarged contrast-enhanced lesions after CCRT, subsequently classified as early tumor progression (n = 42, 53.2%) and pseudoprogression (n = 37, 46.8%). Pseudoprogression was observed in 23 of 24 (95.8%) patients in category 1, 10 of 15 (66.7%) in category 2, four of 20 (20.0%) in category 3, and 0 of 20 (0%) in category 4 (χ(2) test, P < .0001). The histographic pattern of nCBV was the best independent predictor (odds ratio, 3.51; P = .0032) for early tumor progression, rather than each percent change of skewness or kurtosis; the histographic pattern of nCBV represented the largest area under the receiver operating characteristic curve (0.934; 95% confidence interval: 0.855, 0.977), with a sensitivity of 85.7% and a specificity of 89.2%.
CONCLUSION: The percent change of skewness and kurtosis of nCBV may be a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. © RSNA, 2012

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22771885     DOI: 10.1148/radiol.12112120

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  64 in total

Review 1.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

2.  Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis.

Authors:  J Cha; S T Kim; H-J Kim; B-J Kim; Y K Kim; J Y Lee; P Jeon; K H Kim; D-S Kong; D-H Nam
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

Review 3.  Pros and cons of current brain tumor imaging.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Martin J van den Bent; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 4.  MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.

Authors:  Praneil Patel; Hediyeh Baradaran; Diana Delgado; Gulce Askin; Paul Christos; Apostolos John Tsiouris; Ajay Gupta
Journal:  Neuro Oncol       Date:  2016-08-08       Impact factor: 12.300

5.  How treatment monitoring is influencing treatment decisions in glioblastomas.

Authors:  Martha R Neagu; Raymond Y Huang; David A Reardon; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 6.  Radiomics as a Quantitative Imaging Biomarker: Practical Considerations and the Current Standpoint in Neuro-oncologic Studies.

Authors:  Ji Eun Park; Ho Sung Kim
Journal:  Nucl Med Mol Imaging       Date:  2018-02-01

Review 7.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

8.  Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.

Authors:  Andrea Romano; Luca Pasquini; Alberto Di Napoli; Francesca Tavanti; Alessandro Boellis; Maria Camilla Rossi Espagnet; Giuseppe Minniti; Alessandro Bozzao
Journal:  J Neurooncol       Date:  2018-05-02       Impact factor: 4.130

9.  Joint arterial input function and tracer kinetic parameter estimation from undersampled dynamic contrast-enhanced MRI using a model consistency constraint.

Authors:  Yi Guo; Sajan Goud Lingala; Yannick Bliesener; R Marc Lebel; Yinghua Zhu; Krishna S Nayak
Journal:  Magn Reson Med       Date:  2017-09-14       Impact factor: 4.668

Review 10.  Advanced MR Imaging in Neuro-oncology.

Authors:  A Radbruch; M Bendszus
Journal:  Clin Neuroradiol       Date:  2015-07-29       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.